CRESCENT-HEALTHCARE
The US Society of Robotic Surgery and Crescent Healthcare (a Division of the Crescent Group of Companies) host the first Global Robotic MedTech Forum in the Middle East on 16 March 2023 in Dubai. The event, the first dedicated global forum to gather world renowned experts in the region, will focus on the latest advancements in robotic surgery, a rapidly growing field that is revolutionizing healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005505/en/
His Excellency AbdulRahman bin Mohamed Al Owais, UAE Minister of Health and Prevention (Photo: AETOSWire)
The Forum will host ministers, senior government officials, as well as healthcare, R&D and investment professionals to discuss the future of robotic assisted surgery, in addition to the UAE’s leading position at the cutting-edge of healthcare.
His Excellency AbdulRahman bin Mohamed Al Owais, UAE Minister of Health and Prevention, commented: "As we navigate the challenges of modern healthcare, the UAE is proud to host the Global Robotic MedTech Forum. By embracing technology and innovation, we can further improve patient outcomes and provide more efficient and effective healthcare solutions for all."
Dr. Vipul Patel, President, Society of Robotic Surgery, and one of the world's most experienced robotic surgeons said: "The Forum will provide a unique platform for knowledge exchange and explore innovative solutions that can vastly help improve patient outcomes."
Mr. Hamid Jafar, Chairman of the Crescent Group of Companies, which is hosting the event, said: "The Global Robotic MedTech Forum is an important platform that brings together industry leaders to drive meaningful advancements in the healthcare sector. We are pleased to host this event and look forward to enabling the sharing of insights and knowledge in this exciting field."
Dr. Fred Moll, Founder of Intuitive Surgical and a pioneer of robotic surgery, said: "Honored to be part of the Forum and have the opportunity to share insights on the future of robotic surgery with fellow innovators and industry leaders."
Neeraj Agrawal, Board Member of EndoQuest, said: "This event brings together the best and brightest global minds in the field to the Gulf region, and we are honored to participate."
Kurt Azarbarzin, CEO of EndoQuest, added: "We are excited to present the latest innovations in scarless incisionless robotic surgery deploying flexible robots through natural human orifices."
Eduardo Fonseca, Board Member of XCath, commented: “From advanced imaging and sensors to cutting-edge robotics and AI, the possibilities for enhancing patient outcomes and improving the quality of care are endless. The Gulf region will be at the forefront of the development of groundbreaking technologies that have the potential to transform the healthcare industry."
The Global Robotic MedTech Forum will feature some of the most prominent global figures in the field of robotic surgery including Dr. Chris Thompson, Professor at Harvard University who has been at the forefront of developing and testing new robotic surgical techniques. Dr. Santiago Horgan, the Director of UC San Diego’s Center for the Future of Surgery will also share his insights. The participation of these distinguished experts underscores the importance of the Global Robotic MedTech Forum as a platform for sharing knowledge and advancing the field of robotic medicine.
The Forum will feature keynote speeches from leading experts in the field, interactive panel discussions, and hands-on demonstrations of the latest robotic surgical systems. Attendees will have the opportunity to learn about the latest advancements in the field, and to see first-hand how robotic surgery is rapidly changing the face of healthcare globally.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom